Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling
Objective: Lymphatic metastasis is one of the leading causes of malignancy dispersion in various types of cancer. However, few anti-lymphangiogenic drugs have been approved for clinical use to date. Therefore, new therapies to block lymphangiogenesis are urgently required. Methods: Immunohistochemis...
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | Article |
| Langue: | English |
| Publié: |
China Anti-Cancer Association
2020-08-01
|
| Collection: | Cancer Biology & Medicine |
| Sujets: | |
| Accès en ligne: | http://www.cancerbiomed.org/index.php/cocr/article/view/1681 |